Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Video Abstracts
  • Reviews
    • View all reviews ...
    • Pancreatic Cancer (Jul 2025)
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • Microbiome in Health and Disease (Feb 2025)
    • Substance Use Disorders (Oct 2024)
    • Clonal Hematopoiesis (Oct 2024)
    • Sex Differences in Medicine (Sep 2024)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Video Abstracts
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
Mast cell–derived factor XIIIA contributes to sexual dimorphic defense against group B streptococcal infections
Adrian M. Piliponsky, … , Adam J. Moeser, Lakshmi Rajagopal
Adrian M. Piliponsky, … , Adam J. Moeser, Lakshmi Rajagopal
Published August 25, 2022
Citation Information: J Clin Invest. 2022;132(20):e157999. https://doi.org/10.1172/JCI157999.
View: Text | PDF
Research Article Cell biology Infectious disease Article has an altmetric score of 2

Mast cell–derived factor XIIIA contributes to sexual dimorphic defense against group B streptococcal infections

  • Text
  • PDF
Abstract

Invasive bacterial infections remain a major cause of human morbidity. Group B streptococcus (GBS) are Gram-positive bacteria that cause invasive infections in humans. Here, we show that factor XIIIA–deficient (FXIIIA-deficient) female mice exhibited significantly increased susceptibility to GBS infections. Additionally, female WT mice had increased levels of FXIIIA and were more resistant to GBS infection compared with isogenic male mice. We observed that administration of exogenous FXIIIA to male mice increased host resistance to GBS infection. Conversely, administration of a FXIIIA transglutaminase inhibitor to female mice decreased host resistance to GBS infection. Interestingly, male gonadectomized mice exhibited decreased sensitivity to GBS infection, suggesting a role for gonadal androgens in host susceptibility. FXIIIA promoted GBS entrapment within fibrin clots by crosslinking fibronectin with ScpB, a fibronectin-binding GBS surface protein. Thus, ScpB-deficient GBS exhibited decreased entrapment within fibrin clots in vitro and increased dissemination during systemic infections. Finally, using mice in which FXIIIA expression was depleted in mast cells, we observed that mast cell–derived FXIIIA contributes to host defense against GBS infection. Our studies provide insights into the effects of sexual dimorphism and mast cells on FXIIIA expression and its interactions with GBS adhesins that mediate bacterial dissemination and pathogenesis.

Authors

Adrian M. Piliponsky, Kavita Sharma, Phoenicia Quach, Alyssa Brokaw, Shayla Nguyen, Austyn Orvis, Siddhartha S. Saha, Nyssa Becker Samanas, Ravin Seepersaud, Yu Ping Tang, Emily Mackey, Gauri Bhise, Claire Gendrin, Anna Furuta, Albert J. Seo, Eric Guga, Irina Miralda, Michelle Coleman, Erin L. Sweeney, Charlotte A. Bäuml, Diana Imhof, Jessica M. Snyder, Adam J. Moeser, Lakshmi Rajagopal

×

Figure 8

GBS ScpB forms protein complexes with fibronectin and attenuates GBS dissemination.

Options: View larger image (or click on image) Download as PowerPoint
GBS ScpB forms protein complexes with fibronectin and attenuates GBS dis...
(A) FXIIIA-mediated crosslinking between purified ScpB and fibronectin. ScpB (2 μM) was incubated with fibronectin (1 μM) and FXIIIA (30 μg/mL) in TBS, pH 7.4, 5 mM CaCl2 buffer at 25°C from 0 to 240 minutes. Aliquots were removed at the indicated times and were separated on SDS-PAGE, followed by Western blotting with either the anti-ScpB (top panel) or anti-fibronectin (bottom panel) antibodies. Controls included ScpB alone, fibronectin (FN) alone, or samples lacking FXIIIA. Arrows indicate the positions of the ScpB, FN, and products of the crosslinking reaction, which are depicted as P1, P2, and P3. A representative blot from 3 independent experiments is shown. (B) WT B6 mice were infected i.p. with 0.5 to 1 × 108 CFU of WT GBS strain COH1, isogenic ScpB-deficient GBS (ΔscpB), or the complemented strain(ΔscpB/pScpB). At 24 hours after infection, bacterial burden was evaluated in blood, peritoneal fluids, spleen, and lungs. Data are shown as medians with boxes representing values from individual mice. *P < 0.05; **P < 0.01, Kruskal-Wallis test with Dunn’s multiple-comparison test.

Copyright © 2025 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts

Posted by 4 X users
14 readers on Mendeley
See more details